Stem Cell Therapy International said it has secured short-term funding to finalize its merger with HistoStem, a South Korean firm that manages a cord blood and stem cell bank, to create a firm called AmStem International. Under the merger, AmStem is expected to bring to the U.S. adult stem cells from Asia for use in clinical studies and treatments.

Related Summaries